Dr. Lal PathLabs Q2 Results: Dr. Lal PathLabs Ltd reported a significant increase in net profit for the second quarter of FY25. The company’s net profit rose 18% year-on-year, reaching Rs 130.80 crore for the three months ending in September.
The revenue for the period showed a solid growth of 9.8%, amounting to Rs 660.20 crore. This upward trend reflects the company’s continued strength in the diagnostic and healthcare testing services sector.
Earnings before interest, taxes, depreciation, and amortization (EBITDA) also experienced a notable rise, increasing by 14% to Rs 202.50 crore. This growth indicates improved operational efficiency.
Also Read: IREDA Shares Decline 9.31% to Four-Month Low as Q2 Profit Misses Estimates; know more on this
The EBITDA margin improved slightly to 30.7%, up from 29.6% in the previous year, showcasing the company’s ability to enhance profitability despite rising revenues.
Despite the strong financial performance, shares of Dr. Lal PathLabs closed 1.64% lower, in contrast to a minor 0.17% decline in the benchmark Sensex.